Actelion Ltd – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "Actelion Ltd - Product Pipeline Review - 2012" provides data on the Actelion Ltd's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Actelion Ltd's corporate website, SEC filings, investor presentations and featured press releases, both from Actelion Ltd and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- Actelion Ltd - Brief Actelion Ltd overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Actelion Ltd human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Actelion Ltd with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Actelion Ltd's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Actelion Ltd's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Actelion Ltd in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Actelion Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Actelion Ltd.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Actelion Ltd and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Actelion Ltd; Actelion Ltd - Key Therapeutics; Actelion Ltd - Pipeline Overview and Promising Molecules; Actelion Ltd - News; Actelion Ltd - Latest Updates; Actelion Ltd - Pipeline; Actelion Ltd - Discontinued/Dormant Projects
Table of Contents
Table of Contents
List of Tables
List of Figures
Actelion Ltd Snapshot
Actelion Ltd Overview
Key Information
Key Facts
Actelion Ltd – Research and Development Overview
Key Therapeutic Areas
Actelion Ltd – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Actelion Ltd – Pipeline Products Glance
Actelion Ltd – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Actelion Ltd Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Actelion Ltd – Drug Profiles
ACT-280778
Product Description
Mechanism of Action
R&D Progress
ACT-434964
Product Description
Mechanism of Action
R&D Progress
Cadazolid
Product Description
Mechanism of Action
R&D Progress
CRTH2 Receptor Antagonist
Product Description
Mechanism of Action
R&D Progress
Drug For Cardiovascular Disorders
Product Description
Mechanism of Action
R&D Progress
Drug For Immunological Disorders
Product Description
Mechanism of Action
R&D Progress
Drug For Malaria
Product Description
Mechanism of Action
R&D Progress
Macitentan
Product Description
Mechanism of Action
R&D Progress
Macitentan + Temozolomide
Product Description
Mechanism of Action
R&D Progress
Orexin Receptor Antagonist
Product Description
Mechanism of Action
R&D Progress
Ponesimod
Product Description
Mechanism of Action
R&D Progress
S1P1 Agonist
Product Description
Mechanism of Action
R&D Progress
Selexipag
Product Description
Mechanism of Action
R&D Progress
Tracleer
Product Description
Mechanism of Action
R&D Progress
Actelion Ltd – Pipeline Analysis
Actelion Ltd – Pipeline Products by Therapeutic Class
Actelion Ltd – Pipeline Products By Target
Actelion Ltd – Pipeline Products by Route of Administration
Actelion Ltd – Pipeline Products By Mechanism of Action
Actelion Ltd – Recent Pipeline Updates
Actelion Ltd - Dormant Projects
Actelion Ltd - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ACT-129968
Almorexant
Palosuran
Pivlaz
Actelion Ltd – Company Statement
Actelion Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Actelion Ltd, Recent Developments
Actelion Ltd- Press Release
Apr 30, 2012: Actelion's Macitentan Meets Primary Endpoint In Pivotal Phase III SERAPHIN Outcome Study In Patients With Pulmonary Arterial Hypertension
Apr 02, 2012: Actelion Provides Update On CRTH2 Program
Feb 01, 2012: Experimental Drug Clazosentan Reduces Second Stroke After Aneurysm Rupture
Dec 21, 2009: Actelion Announces Phase III Study Results Of Almorexant (RESTORA 1) For The Treatment Of Sleep Disorders
Dec 08, 2009: Actelion's selective S1P1 receptor agonist moves into advanced clinical development in psoriasis - Phase IIb dose-finding study in multiple sclerosis already ongoing - Roche to leave S1P1 alliance following comprehensive portfolio review and prioritization
Oct 12, 2009: Actelion Announced The Beginning Of The Phase Iib Study Of Act-128800 In Patients With Multiple Sclerosis.
Oct 09, 2009: Actelion Ltd Announces Dose-Finding Phase IIb Study Started In Patients With Multiple Sclerosis
Financial Deals Landscape
Actelion Ltd, Deals Summary
Actelion Ltd, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Actelion Acquires Rights Of Epoprostenol From GeneraMedix
Partnerships
Basilea Enters Into Distribution Agreement With Actelion
Actelion Extends Collaboration With Invida Pharma
Actelion Enters Into An Agreement With Medexus
TI Pharma Enters Into Co-Development Agreement With Actelion, Erasmus And Maastricht University
Nippon Shinyaku Enters Into Agreement With Actelion Pharma
Roche Enters Into Co-Development Agreement With Actelion
CoTherix Enters Into Collobrative Research Agreement With Quadrant Drug Delivery
Accredo Health Enters Into Distribution Agreement With CoTherix
Licensing Agreements
Nippon Shinyaku Signs Licensing Agreement With Actelion
Asahi Kasei Pharma Enters Into Licensing Agreement With CoTherix
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug
GlaxoSmithKline Enters Into An Agreement With Actelion
Actelion Enters Into Licensing Agreement With Nippon Shinyaku For Japan
Actelion Extends Licensing Agreement With Celltech For Zavesca
CoTherix Enters Into Licensing Agreement With California State University Bakersfield Foundation For Nikkomycin-z
Equity Offering
CoTherix Completes Public Offering Of $56 Million
CoTherix Completes Public Offering Of $38 Million
CoTherix Completes IPO Of $30 Million
Debt Offering
Actelion Pharma Completes Public Offering Of Convertible Bonds For $368 Million
Acquisition
Actelion Acquires CoTherix
Cerep Acquires Hesperion
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Actelion Ltd, Key Information
Actelion Ltd, Key Facts
Actelion Ltd – Pipeline by Indication, 2012
Actelion Ltd – Pipeline by Stage of Development, 2012
Actelion Ltd – Monotherapy Products in Pipeline, 2012
Actelion Ltd – Combination Treatment Modalities in Pipeline, 2012
Actelion Ltd – Phase III, 2012
Actelion Ltd – Phase II, 2012
Actelion Ltd – Phase I, 2012
Actelion Ltd – Pipeline By Therapeutic Class, 2012
Actelion Ltd - Pipeline By Target, 2012
Actelion Ltd – Pipeline By Route of Administration, 2012
Actelion Ltd – Pipeline Products By Mechanism of Action, 2012
Actelion Ltd – Recent Pipeline Updates, 2012
Actelion Ltd - Dormant Developmental Projects,2012
Actelion Ltd - Discontinued Pipeline Products, 2012
Actelion Ltd, Subsidiaries
Actelion Ltd, Deals Summary
Actelion Acquires Rights Of Epoprostenol From GeneraMedix
Basilea Enters Into Distribution Agreement With Actelion
Actelion Extends Collaboration With Invida Pharma
Actelion Enters Into An Agreement With Medexus
TI Pharma Enters Into Co-Development Agreement With Actelion, Erasmus And Maastricht University
Nippon Shinyaku Enters Into Agreement With Actelion Pharma
Roche Enters Into Co-Development Agreement With Actelion
CoTherix Enters Into Collobrative Research Agreement With Quadrant Drug Delivery
Accredo Health Enters Into Distribution Agreement With CoTherix
Nippon Shinyaku Signs Licensing Agreement With Actelion
Asahi Kasei Pharma Enters Into Licensing Agreement With CoTherix
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug
GlaxoSmithKline Enters Into An Agreement With Actelion
Actelion Enters Into Licensing Agreement With Nippon Shinyaku For Japan
Actelion Extends Licensing Agreement With Celltech For Zavesca
CoTherix Enters Into Licensing Agreement With California State University Bakersfield Foundation For Nikkomycin-z
CoTherix Completes Public Offering Of $56 Million
CoTherix Completes Public Offering Of $38 Million
CoTherix Completes IPO Of $30 Million
Actelion Pharma Completes Public Offering Of Convertible Bonds For $368 Million
Actelion Acquires CoTherix
Cerep Acquires Hesperion
List of Figures
Actelion Ltd – Pipeline by Indication, 2012
Actelion Ltd – Pipeline by Stage of Development, 2012
Actelion Ltd – Monotherapy Products in Pipeline, 2012
Actelion Ltd – Combination Treatment Modalities in Pipeline, 2012
Actelion Ltd – Pipeline By Therapeutic Class, 2012
Actelion Ltd - Pipeline By Target, 2012
Actelion Ltd - Pipeline Products By Mechanism of Action, 2012 37
